Drug Type Antibody drug conjugate (ADC) |
Synonyms PBX 003, PBX003 |
Target |
Mechanism EGFR antagonists(Epidermal growth factor receptor erbB1 antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Colorectal Cancer | Preclinical | KR | 11 Jan 2024 | |
Head and Neck Neoplasms | Preclinical | KR | 11 Jan 2024 | |
Lung Cancer | Preclinical | KR | 11 Jan 2024 | |
Pancreatic Cancer | Discovery | KR | 07 Jun 2023 |